Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chymotrypsin-like elastase family member 2A (CELA2A) is a pancreatic serine protease enzyme secreted as a zymogen that hydrolyzes proteins, especially elastin, as well as proteins containing leucine, methionine, and phenylalanine residues. Beyond its canonical digestive role, CELA2A circulates in plasma where it modulates postprandial metabolic signaling. It reduces platelet hyperactivation, triggers both insulin secretion and insulin degradation, increases insulin sensitivity, and is implicated in the pathogenesis of metabolic syndrome and early-onset atherosclerosis when mutated. These diverse effects position CELA2A as an attractive target for therapeutic intervention in metabolic and cardiovascular diseases
Drugs targeting CELA2A would be expected to modulate its protease activity, and thereby influence insulin secretion, insulin degradation, platelet activation, and metabolic homeostasis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chymotrypsin-like elastase family member 2A (CELA2A).